Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP science news

Show

From To
'In complete shock': Sydney man contracts HIV despite taking PrEP drug

Steven Spencer, 27, tested positive for HIV in December, despite diligently using PrEP "on demand" before and after sexual encounters in line with the advice of doctors. "What happened to me doesn’t change the fact that PrEP is still the most powerful HIV preventative we have ever had," said Mr Spencer, one of the first men in Australia to start taking the medication more than five years ago.

Published
5 hours ago
From
Sydney Morning Herald
On-Demand PrEP With TDF/FTC Not Associated With Clinically Relevant Decline in Kidney Function

On-demand pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) is not associated with a significant relevant in kidney function, especially among young people with low pill use and high baseline estimated glomerular filtration rate, investigators in France found.

Published
20 March 2019
From
Contagion Live
Jean-Michel Molina, MD, on Biomedical Failures of PrEP: Rare, But Serious

"There are multiple reasons for PrEP failures and they could be at any point in the PrEP continuum of care. From people who may not use their pills as recommended, to a health care system that is not able to provide access to PrEP for people in need, it could be also the physicians who are not ready to prescribe PrEP or not aware that they could use PrEP for preventing HIV in high-risk patients. It could be also the test that we use sometimes that are not able to detect acute HIV infection. And, if you start PrEP in someone with acute HIV infection you will see more resistance."

Published
14 March 2019
From
Contagion Live
Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a different story.

Published
14 March 2019
From
FiercePharma
TAF: Quick-dissolve combination PrEP insert is effective against HIV infections in monkeys; intermittent solo pill less so

Two studies in monkeys of experimental pre-exposure prophylaxis (PrEP) regimens featuring the drug tenofovir alafenamide (TAF) produced differing results when presented at last week’s Conference on Retroviruses

Published
13 March 2019
By
Gus Cairns
Effective HIV Interventions Have Changed the Approach to Trials

In the past, individuals who were at high risk for HIV infection and who were enrolled in placebo-controlled prevention trials had been typically randomly assigned to either an experimental agent or placebo. However, that trial design—and the way those trials were interpreted—has shifted. This was the topic of discussion during David Dunn’s session yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI) 2019. Dunn is a researcher at University College London in the United Kingdom.

Published
11 March 2019
From
Infectious Diseases Consultant
How many people who have used PrEP get HIV the same year? New York study finds out

One question often asked about pre-exposure prophylaxis (PrEP) use is how frequently people start PrEP while unknowingly having HIV, often because they have acquired it so recently

Published
07 March 2019
By
Gus Cairns
Descovy is non-inferior to Truvada for daily PrEP

A daily pill containing the newer formulation of tenofovir in combination with emtricitabine (Descovy) had a comparable protective effect to the existing daily pill which contains the older

Published
06 March 2019
By
Roger Pebody
55% drop in HIV incidence in gay men in England in just two years

In just two years, the incidence of new HIV infections in men who have sex with men attending English sexual health clinics fell by 55%, according

Published
05 March 2019
By
Roger Pebody
Correlation between HIV, rectal gonorrhea could help PrEP trial designs

Rectal gonorrhea incidence may serve to estimate what HIV incidence would have been had trial participants not received PrEP, according to study findings.

Published
12 February 2019
From
Healio
← First12345...15Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.